AKT1 L52R

CI-VAR-00002357Explore in graph →NP_001369359.1:p.Leu52ArgNM_001382430.1:c.155T>GCIViC 1191

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Endometrial Neoplasm1
AKT1 L52R	Capivasertib	Predictive	C	Supports Sensitivity Response	4	submitted	EID10762 Phase II trial of AKT-inhibitor capivasertib in patients with solid tumors and AKT1/2/3 alterations. One patient with an AKT1 L52R mutant endometrioid cancer achieved partial response that lasted for … (full text at CIViC) PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.